Biotronik Strengthens PTA Balloon Portfolio

Biotronik SE & Co. KG is bolstering its percutaneous transluminal angioplasty (PTA) balloon portfolio with the recently-launched Passeo-35 product line.

The Passeo-35 0.035″ PTA balloon is part of the company’s lower limb product portfolio. The availability of balloon lengths of up to 200 mm in diameters 3-7 mm gives physicians the ability to dilate longer disease segments in lower limb vessels with fewer balloon inflations, which potentially can reduce potential barotrauma caused by multiple inflations and possibly shorten procedure times. In addition, the Passeo-35 0.035″ has an extremely low profile, with a measurement of 7 mm by 200 mm, allowing for balloon compatibility with a 5F introducer sheath, and an excellent secondary profile. The addition of long balloon lengths also creates good synergy with Biotronik’s Pulsar-35 self-expanding stent.

The Passeo-35 HP 0.035″ High Pressure PTA balloon is designed to treat vessel segments that require high pressure dilatation to efface resistant, often fibrotic stenoses (found most often in arterio-venous access fistulae and grafts). Existing PTA balloon treatment options can have compromised flexibility or a bulky profile, or display instability at higher pressures. Passeo-35 HP is designed to deliver high-rated burst pressures of up to 27 atmospheres with uncompromised balloon flexibility. This results from the use of a conformable yet highly durable balloon material, minimizing the risk of vessel straightening but with the strength to dilate resistant lesions. Passeo-35 HP is available in diameters from 3 mm to 12 mm and in balloon lengths from 20 mm to 100 mm.

“These latest additions to our peripheral intervention portfolio underline Biotronik’s commitment to delivering devices in line with the needs and expectations of interventional operators,” said Dr. Alexander Uhl, Biotronik vice president of marketing, Vascular Intervention. “Furthermore, our PTA balloon portfolio is now one of the strongest and most comprehensive available.”

Biotronik is based in Berlin, Germany, and has a global workforce of more than 5,600 employees. Its U.S. headquarters is located in Lake Oswego, Ore.